During the period of our study, 130 neonates were born with IUGR in the University Hospital Bonn. Of these 130 neonates, 62 were not eligible for inclusion because they met at least one of the exclusion criteria. An additional 29 IUGR neonates could not be included as there was no parental consent for participation in the study (Fig.
1). These neonates did not differ significantly from participants in gestational age, birth weight or sex.
Of the neonates participating in the study, 39 were enrolled in the IUGR case group with an average gestational age of 31.90 weeks (standard deviation (SD) 3.46 weeks). Sixty neonates were enrolled in the control group, with an average gestational age of 32.45 weeks (SD 2.91 weeks). As entailed by the definition of IUGR, birth weight was significantly lower in the IUGR group 1.38 kg (SD 0.52 kg) than in the control group 1.96 kg (SD 0.58 kg) (mean
z scores: IUGR group − 1.43, SD 0.58; control group − 0.08, SD 0.58). Consecutively, birth length (39.23 cm, SD 5.12 cm; mean
z score − 1.33, SD 0.74) in the IUGR group was significantly lower than in the control group (43.83 cm, SD 4.48 cm; mean
z score − 0.02, SD 0.88). The mean weight-for-length
z scores were − 3.01 (SD 1.92) in the IUGR group and 0.23 (SD 2.36) in the control group. Expectedly, body weight at discharge was still lower in IUGR patients (2.08 kg, SD 0.28 kg; mean
z score − 2.53, SD 0.66) than in control patients (2.39 kg, SD 0.32 kg; mean
z score − 1.40, SD 0.60,
p < 0.001). The same was true for body length at discharge (IUGR 43.64 cm, SD 1.97 cm; mean
z score − 2.96, SD 0.93; controls 46.74 cm, SD 2.85 cm; mean
z score − 1.22, SD 1.30; corrected
p < 0.001).
Z scores at discharge are based on the corrected gestational age. Other demographic data did not differ (see Table
1). Neonates in the IUGR group were more likely to be treated with blood pressure-increasing drugs like catecholamines and glucocorticoids at the time of the first measurement (BP1) than neonates in the control group. This difference was not significant after Bonferroni correction for multiple comparisons (
p = 0.039). The application of the first line antibiotic tobramycin was comparable in both groups, whereas the IUGR cases received second-line antibiotic treatment with vancomycin non-significantly (
p = 0.039) more frequently during hospitalisation. In every patient, vancomycin and tobramycin were monitored by serum-level controls, and none of the levels measured reached the nephrotoxic range (tobramycin > 12 µg/ml, vancomycin > 30 µg/ml). There was no acute kidney injury (AKI, based on neonatal AKI KDIGO classification [
29]) observed in the participants of the IUGR or the control group. The length of hospitalisation and hence the study period differed between cases and controls, with a median hospital stay of 31 days for IUGR cases compared to 19 days for controls.
Table 1
Clinical characteristics of cases and controls. If data were normally distributed, standard deviation is given and p refers to a t test comparison of means. If data was non-normally distributed, interquartile ranges are provided and p refers to a Mann–Whitney U test. Z scores at discharge refer to the corrected gestational age
Male | 17 (44%) | 28 (47%) | 0.925 |
Birth weight (kg) | 1.38 ± 0.52* | 1.96 ± 0.58* | < 0.001 |
Mean z score | − 1.43 ± 0.58* | − 0.08 ± 0.58* | |
Birth length (cm) | 39.23 ± 5.12* | 43.83 ± 4.48* | < 0.001 |
Mean z score | − 1.33 ± 0.74* | − 0.02 ± 0.88* | |
Weight-for-length (g/cm) | 34.23 ± 9.66* | 44.01 ± 9.95* | |
Mean z score | − 3.01 ± 1.92* | 0.23 ± 2.36* | |
Gestational age (weeks) | 31.90 ± 3.46* | 32.45 ± 2.91* | 0.416 |
Umbilical artery pH | 7.34 [7.27; 7.38]** | 7.36 [7.28; 7.39]** | 0.376 |
Treatment with nephrotoxic drugs | | | |
Vancomycin | 10 (26%) | 5 (8%) | 0.039 |
Tobramycin | 16 (41%) | 21 (35%) | 0.694 |
Treatment with BP-modifying drugs | | | |
BP-increasing 36th–72nd hour of life | 10 (26%) | 5 (8%) | 0.039 |
BP-decreasing 36th–72nd hour of life | 14 (36%) | 16 (27%) | 0.452 |
BP-increasing 8th day of life | 3 (8%) | 2 (3%) | 0.380*** |
BP-decreasing 8th day of life | 3 (8%) | 7 (12%) | 0.736*** |
BP-decreasing before discharge | 3 (8%) | 2 (3%) | 0.380*** |
Body weight at discharge (kg) | 2.08 ± 0.28* | 2.39 ± 0.32* | < 0.001 |
Mean z score | − 2.53 ± 0.66* | − 1.40 ± 0.60* | |
Body length at discharge (cm) | 43.64 ± 1.97* | 46.74 ± 2.85* | < 0.001 |
Mean z score | − 2.96 ± 0.93* | − 1.22 ± 1.30* | |
Length of hospitalisation (days) | 31 [19.5; 74]** | 19 [12.75; 37.25]** | 0.0486 |
Maternal age (years) | 30.9 ± 5.5* | 32.9 ± 4.6* | 0.069 |
Maternal BMI (kg/m2) | 24.4 [20.9; 27.9]** | 23.9 [21.5; 27.3]** | 0.969 |
Gravida | | | 0.810 |
1 | 17 (44%) | 26 (43%) | |
2 | 11 (28%) | 14 (23%) | |
≥ 3 | 11 (28%) | 20 (33%) | |
Multiple pregnancy | 15 (38%) | 31 (52%) | 0.280 |
Vaginal delivery | 5 (13%) | 14 (23%) | 0.300 |
Drug abuse in pregnancy | 8 (21%) | 4 (7%) | 0.081*** |
Induced lung maturation | 23 (59%) | 36 (60.0%) | 1.000 |